Bionano Genomics Earnings Call: Growth Amid Cash Burn

Bionano Genomics ((BNGO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Bionano Genomics’ latest earnings call painted a cautiously upbeat picture, with record demand for its optical genome mapping consumables, improved margins, and better reimbursement support. At the same time, management acknowledged lumpy revenue, rising operating expenses, ongoing cash burn, and a limited cash runway, underscoring that execution risk remains high despite clear commercial traction.

Steady Revenue Growth and Guidance Reaffirmed

Bionano posted Q1 2026 revenue of $6.7 million, up 4% year over year and landing at the high end of its guidance range. Management reaffirmed full‑year 2026 revenue guidance of $30 million to $33 million and set Q2 expectations at $7.5 million to $7.8 million, implying double‑digit growth over the prior year’s quarter.

Record Flow Cell Sales Signal Stronger Utilization

The company sold 8,178 nanochannel array flow cells in Q1, a 17% year‑over‑year increase and the highest first‑quarter volume in its history. Notably, flow cell sales to existing customers rose 21% after excluding units tied to new system installations, suggesting optical genome mapping is gaining traction as a routine test rather than a one‑off purchase.

Consumables Strength and Recurring Revenue Momentum

Consumables revenue climbed to $3.9 million in Q1, up 20% versus the same period last year, underscoring greater recurring use of the company’s platforms. Other revenue reached $1.6 million, a 36% year‑over‑year increase that points to a slow but important shift toward a more durable and predictable revenue base.

Gross Margin Improvement and Operational Gains

Adjusted gross margin rose to 49% in Q1 2026, up from 46% a year ago, driven by operational efficiencies and a richer mix of higher‑margin consumables and software. This margin expansion is critical for the long‑term model as the company works to narrow losses while scaling its installed base and recurring revenue streams.

Reimbursement Wins Improve Test Economics

Management highlighted two key reimbursement milestones that took effect in Q1 and meaningfully enhance test economics for customers. Payment for optical genome mapping in hematologic malignancies increased about 47% to roughly $1,850, while a separate code for constitutional disorders received a similar payment level to prior hematology rates, which should lower adoption barriers in both segments.

Scientific Validation and Clinical Uptake Accelerate

The quarter saw a surge in scientific output, with 28 optical genome mapping publications in rare diseases, representing about 56% growth year over year. Published genomes reached 1,991 in Q1, up roughly 158%, and major studies from leading centers reported that optical genome mapping outperformed traditional methods in multiple myeloma, supporting its inclusion in standard diagnostic workflows.

Events and Community Engagement Build Visibility

Bionano’s 2026 Symposium drew more than 1,250 registrants from 73 countries, showcasing large‑scale optical genome mapping use cases. Presentations included plans for laboratories running thousands of samples per year and one Stratus deployment processing 10,000 cancer samples annually, signaling a shift from early pilots toward scaled clinical and research adoption.

Balance Sheet Simplification Through Debt Retirement

The company ended Q1 with $24.7 million in cash, cash equivalents, and securities, including $10.3 million that is restricted. Management expects to fully retire its senior secured convertible debt in May 2026, which will simplify the capital structure and remove a potential overhang for equity investors, albeit without eliminating the need for future funding.

Lumpy Software Revenue Highlights Mix Risk

Software revenue fell 40% year over year to $1.2 million in Q1, a sharp decline tied to a very large prior‑year sale that is expected to cover customer needs through 2026. While this dynamic reflects strong historical deals, it also exposes the company to quarter‑to‑quarter volatility and makes short‑term revenue trends less predictable for investors.

Rising Operating Expenses and Ongoing Cash Burn

Adjusted operating expenses increased to $9.1 million in Q1 2026 from $8.5 million a year earlier, reflecting continued investment in commercialization and R&D. With revenue of $6.7 million well below operating costs, Bionano remains meaningfully cash‑flow negative, a reality that will continue to weigh on valuation until the gap narrows.

Supply Constraints Temper Near‑Term Upside

Management reported that constraints in flow cell production entering the quarter limited available supply and likely capped near‑term revenue. These bottlenecks started to ease during Q1 and are expected to improve further through 2026, suggesting some latent demand may convert into sales as manufacturing capacity catches up.

Revenue Mix and Predictability Remain a Concern

Despite healthy consumables growth, Bionano’s reliance on large, infrequent software deals and prior one‑time purchases continues to inject noise into quarterly results. This mix complicates forecasting and can mask underlying adoption trends, leaving investors to balance solid operational indicators against more volatile top‑line patterns.

Guidance and Outlook Emphasize Growth with Caution

For 2026, management is sticking to revenue guidance of $30 million to $33 million, implying mid‑single to mid‑teens percentage growth over 2025, and expects Q2 revenue to rise 12% to 16% year over year. The company sees margin gains, higher consumables usage, improving reimbursement, and expanding clinical evidence as key growth drivers but does not expect operating cash‑flow breakeven in 2026 and only targets burn reductions toward late 2027.

Bionano’s earnings call painted a story of a company gaining commercial and clinical momentum while still wrestling with scale, volatility, and funding needs. For investors, the appeal lies in strengthening utilization, reimbursement, and margin trends, but the path to sustainable profitability remains long, making execution on growth and cost control the critical variables to watch.